Personalized medicine can help guide treatment decisions for patients with breast cancer



The only test that answers

three clinical questions, to provide you
and your physician with better information
that can impact your treatment.

What is my risk of this cancer returning?

Can I consider safely forgoing chemotherapy?

Will I still need hormone therapy after 5 years?

Visit EndoPredict.com to learn more.

EndoPredict is designed for women with ER+, HER2early-stage breast cancer (node-negative or nodepositive (1-3 nodes), pre- or postmenopausal)







MYRIAD GENETIC LABORATORIES, INC. 320 Wakara Way • Salt Lake City, Utah 84108 Phone: (844) 887-3636 | Fax: (801) 583-8248

Email: EndoPredict@Myriad.com

TO AVOID DELAYS PLEASE COMPLETE ENTIRE FORM

,					
PATIENT INFORMATION			ORDERING PHYSICIAN (Only fi	ll out first line unless nev	v customer or HCP# is unknown)
PATIENT NAME (LAST, FIRST, INITIAL)			NAME (LAST, FIRST, DEGREE)		MYRIAD HCP ACCOUNT NO: (If known)
PATIENT ID # (OPTIONAL)	O FEMALE	BIRTH DATE (MM/DD/YYYY)	NPI#	E-MAIL ADDRESS	
	O MALE		1000500		
STREET ADDRESS			ADDRESS		
CITY	STATE	ZIP	CITY	STATE	ZIP
DAYTIME PHONE NUMBER			OFFICE CONTACT	PHONE	FAX
E-MAIL			EMAIL		
CLINICAL INFORMATION					
_	X:	Procedure (surgery o	r biopsy) Date:	(MM/DD/YYYY)	
☐ Left Breast ☐ Right Breast	Λ		Totopsy/ bute.	(MM/00/1111)	
Tumor Stage: ○ pT1a (> 0.5 cm) ○ pT1b (> 0.5 cm but ≤ 1 cm) ○ pT1c (> 1 cm but ≤ 2 cm) ○ pT2 (> 2 cm but ≤ 5 cm) ○ pT3 (> 5 cm) ○ pTx					
Lymph Node Status: O pN0 (zero positive nodes) O pN1 (1-3 positive nodes; excluding pNmi) O pN1mi (>0.2 mm and/or >200 cells but <2mm) O pNx					
For Medicare Patients Only:					
At the time of procedure: O Hospit	al Inpatient (>24	hour stay) Discharge Date	:(MM/DD/YYY	O Hospital Outp	atient O Non-Hospital Patient
TEST REQUESTED					
EndoPredict - a gene expression test to determine breast cancer prognosis. The test provides a 12-Gene Molecular Score. This can be combined with tumor size and node status to calculate an EPclin Risk Score, and the associated likelihood of distant cancer recurrence up to 10 years after invasive breast cancer diagnosis. Reported 10-year recurrence risks are based on analysis of a cohort of post-menopausal women with resected ER+/ HER2- invasive female breast cancer who have NOT been treated prior to resection with systemic neo-adjuvant therapy (e.g., chemotherapy, radiation therapy or endocrine therapy) and who do not have a current or prior diagnosis of an additional cancer. Risks may differ for individuals who do not meet the aforementioned clinical characteristics. This test is not appropriate for patients who have already experienced a distant recurrence.					
SPECIMEN INFORMATION					
Sample Fixative (check one): 0 10% neutral buffered formalin 0 Other (describe):					
Tissue Type Submitted: O Breast Resection (preferred) O Breast Biopsy					
Date Specimen Retrieved from Archive:		• •	D/YYYY)		
SPECIMEN RETRIEVAL					
O I want Myriad Genetic Laboratories, Inc. to request the specimen. (COMPLETE the information below.)					
LOCATION OF SPECIMEN		PHONE	FAX		CONTACT NAME
AUTHORIZED SIGNATURE					
I hereby authorize testing and confirm that informed consent has been obtained, if required by state law. I hereby attest that the person listed in the Ordering Physician space above is authorized by law in the relevant jurisdiction to order the test(s) requested herein. By signing this form I attest that the patient meets the inclusion criteria stated in the Test Requested section above.					
			HEALTHCARE PROVIDER'S SIGN	ATURE	DATE (MM/DD/YYYY)
BILLING/PAYMENT INFORMATION					
OPTION 1: PLEASE BILL INSURANCE (For Medicare patients: only available if test order date is more than 2 weeks after discharge date)					
Include enlarged copies of both sides of insurance card(s). If two cards are submitted, indicate which is primary.					
OPTION 2: PATIENT PAYMENT (Please ca	all Customer Servic	e for questions regarding test p	prices)		
O OPTION 3: OTHER BILLING (To establish	an account, submit	t billing information with this for	m)		
O Bill our institutional account #:		or established research pr	oject code #:	<i>or</i> Authorization/V	/oucher #: